Alobresib
- Generic Name
- Alobresib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N5O2
- CAS Number
- 1637771-14-2
- Unique Ingredient Identifier
- 3QBL0BLP3D
- Background
Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer).
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
Phase 1
Terminated
- Conditions
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT02607228
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Phase 1
Completed
- Conditions
- Solid Tumors and Lymphomas
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 33
- Registration Number
- NCT02392611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath